Engineered CD3 antibodies for immunosuppression.
作者信息
Renders L, Valerius T
出版信息
Clin Exp Immunol. 2003 Sep;133(3):307-9. doi: 10.1046/j.1365-2249.2003.02227.x.
Abstract
摘要
相似文献
1
Engineered CD3 antibodies for immunosuppression.
Clin Exp Immunol. 2003 Sep;133(3):307-9. doi: 10.1046/j.1365-2249.2003.02227.x.
2
New insights into therapy with monoclonal antibodies in allograft transplantation.
Nephrol Dial Transplant. 1997;12 Suppl 1:55-8.
3
4
Current status of immunosuppressive agents for solid organ transplantation in children.
Pediatr Transplant. 2012 Mar;16(2):106-22. doi: 10.1111/j.1399-3046.2012.01644.x.
5
Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.
Drugs. 1996 May;51(5):865-94. doi: 10.2165/00003495-199651050-00010.
6
Treatment of acute kidney allograft rejection with the nonmitogenic CD3 mAb CLB T3/4.A (IgA-CD3): absence of a correlation of clinical responsiveness with inhibition of lymphocyte reactivity in vitro.
Transplant Proc. 2001 Feb-Mar;33(1-2):1229-30. doi: 10.1016/s0041-1345(00)02399-x.
7
Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy.
Transplant Proc. 1996 Apr;28(2):943-4.
8
OKT3 prophylaxis in kidney transplant recipients: drug monitoring by flow cytometry.
Transplant Proc. 1996 Dec;28(6):3214-6.
9
Use of antilymphocyte induction therapy in liver transplantation: A European perspective.
Liver Transpl Surg. 1999 Jul;5(4 Suppl 1):S71-84. doi: 10.1053/JTLS005s00071.
10
A drug of the past, a lesson for the future.
Pediatr Transplant. 2005 Jun;9(3):267-8. doi: 10.1111/j.1399-3046.2005.00332.x.
引用本文的文献
1
Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial.
J Clin Immunol. 2015 May;35(4):399-407. doi: 10.1007/s10875-015-0160-6. Epub 2015 Apr 17.
2
Obesity increases the production of proinflammatory mediators from adipose tissue T cells and compromises TCR repertoire diversity: implications for systemic inflammation and insulin resistance.
J Immunol. 2010 Aug 1;185(3):1836-45. doi: 10.4049/jimmunol.1000021. Epub 2010 Jun 25.
3
Muronomab-CD3 for pediatric acute myocarditis.
Pediatr Cardiol. 2007 Jan-Feb;28(1):21-6. doi: 10.1007/s00246-006-1322-3. Epub 2006 Dec 7.
本文引用的文献
1
Treatment of acute kidney allograft rejection with a non-mitogenic CD3 antibody.
Clin Exp Immunol. 2003 Sep;133(3):485-92. doi: 10.1046/j.1365-2249.2003.02200.x.
2
FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy.
Tissue Antigens. 2003 Mar;61(3):189-202. doi: 10.1034/j.1399-0039.2003.00037.x.
3
Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).
J Clin Invest. 2003 Feb;111(3):409-18. doi: 10.1172/JCI16090.
4
CD3-specific antibody-induced active tolerance: from bench to bedside.
Nat Rev Immunol. 2003 Feb;3(2):123-32. doi: 10.1038/nri1000.
5
Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.
J Rheumatol. 2002 Sep;29(9):1907-13.
6
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
N Engl J Med. 2002 May 30;346(22):1692-8. doi: 10.1056/NEJMoa012864.
7
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.
Blood. 2002 Apr 15;99(8):2712-9. doi: 10.1182/blood.v99.8.2712.
8
Therapeutic approaches for transplantation.
Curr Opin Immunol. 2001 Oct;13(5):606-10. doi: 10.1016/s0952-7915(00)00268-5.
9
IgA antibodies for cancer therapy.
Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):69-77. doi: 10.1016/s1040-8428(01)00105-6.
10
Molecular basis for immune complex recognition: a comparison of Fc-receptor structures.
J Mol Biol. 2001 Jun 8;309(3):737-49. doi: 10.1006/jmbi.2001.4670.
Zotero 插件